Bomalaski, John S.

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

Izzo, F., Marra, P., Beneduce, G., Castello, G., Vallone, P., De Rosa, V., Cremona, F., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., et al. (2004) · Journal of Clinical Oncology

Bacterial Cancer TherapyHepatocellular Carcinoma Treatment and Prognosis

Cited by 250

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

Ascierto, P. A., Scala, S., Castello, G., Daponte, A., Simeone, E., Ottaiano, A., Beneduce, G., De Rosa, V., Izzo, F., Melucci, M. T., et al. (2005) · Journal of Clinical Oncology

Bacterial Cancer TherapyMelanoma and MAPK Pathways

Cited by 238

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Ott, P. A., Carvajal, R. D., Pandit-Taskar, N., Jungbluth, A. A., Hoffman, E. W., Wu, B.-W., Bomalaski, J. S., Venhaus, R., Pan, L., Old, L. J., et al. (2013) · Investigational New Drugs

Bacterial Cancer TherapyAmino Acid Enzymes and Metabolism

Cited by 146

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

Feun, L. G., Marini, A., Walker, G., Elgart, G., Moffat, F., Rodgers, S. E., Wu, C. J., You, M., Wangpaichitr, M., Kuo, M. T., et al. (2012) · British Journal of Cancer

Bacterial Cancer TherapyCancer Immunotherapy and Biomarkers

Cited by 113